Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
53
Language
English
Published on
22/02/24
You may also be interested by these reports :
04/06/26
Over the 5 days to 02-06, 18 pharma stocks out of the 23 under coverage fell. The sector performance chart is not looking good. We see an opportunity ...
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...
30/05/26
With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex ...
28/05/26
Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent ...